A 62-year-old man with newly diagnosed Parkinson disease presents with bradykinesia, rigidity, and resting tremor. He has no cognitive impairment, no orthostatic hypotension, and normal cardiac function. What is the drug of choice for initiating monotherapy in this patient?

Explanation

## Drug of Choice for Initiating Monotherapy in Parkinson Disease **Key Point:** Levodopa combined with carbidopa (a peripheral dopa-decarboxylase inhibitor) remains the **gold standard and most effective drug** for symptomatic treatment of Parkinson disease. For a 62-year-old patient with significant motor symptoms (bradykinesia, rigidity, resting tremor), levodopa/carbidopa is the drug of choice for initiating monotherapy. **High-Yield:** While the historical teaching favored dopamine agonists in younger patients to "delay dyskinesia," current evidence and major guidelines (AAN, Movement Disorder Society) recognize that levodopa/carbidopa provides superior motor symptom control, better quality of life, and is well-tolerated even in patients under 70. The fear of early dyskinesia with levodopa has been overstated — dyskinesias are dose- and duration-dependent and can be managed. ## Comparison of Monotherapy Options in Early PD | Agent | Class | Role | Advantage | Limitation | |-------|-------|------|-----------|------------| | **Levodopa + Carbidopa** | Dopamine precursor | **First-line DOC** | Most potent; best motor control; superior QoL | Long-term dyskinesia risk (manageable) | | Pramipexole | Non-ergot DA (D2/D3) | Alternative in very young patients | Delays dyskinesia onset | Less efficacious; somnolence; impulse control disorders | | Selegiline | MAO-B inhibitor | Adjunct or very mild PD | Mild symptomatic benefit | Insufficient as monotherapy for significant symptoms | | Amantadine | NMDA antagonist | Adjunct for dyskinesia | Reduces dyskinesia | Not first-line monotherapy | **Clinical Pearl (KD Tripathi / Harrison):** Levodopa is the most effective antiparkinsonian drug. Carbidopa inhibits peripheral decarboxylation of levodopa, reducing peripheral side effects (nausea, vomiting, cardiac arrhythmias) and allowing more levodopa to enter the CNS. The combination is the **drug of choice** for Parkinson disease monotherapy across all age groups with significant motor disability. ## Why Levodopa/Carbidopa Over Pramipexole Here? - **Age 62 with significant motor symptoms:** The patient has bradykinesia, rigidity, AND resting tremor — three cardinal features requiring effective symptom control. Levodopa provides the most robust relief. - **No contraindications:** The patient has no cognitive impairment, no orthostatic hypotension, and normal cardiac function — all of which would otherwise favor one agent over another. - **NEET PG / INI-CET standard:** Per KD Tripathi (Essentials of Medical Pharmacology) and standard Indian PG exam teaching, levodopa + carbidopa is the **drug of choice** for Parkinson disease. - **Dopamine agonist preference** applies primarily to patients <60 years (very young onset) where the cumulative dyskinesia burden over decades is a major concern — not a 62-year-old with established motor symptoms. **Tip:** Pramipexole may be preferred as an alternative in patients <60 years with very mild symptoms to delay motor complications, but levodopa/carbidopa remains the standard DOC for initiating therapy in Parkinson disease, especially with significant motor features. **Reference:** KD Tripathi, Essentials of Medical Pharmacology, 8th ed., Chapter on Antiparkinsonian Drugs; Harrison's Principles of Internal Medicine, 21st ed., Chapter on Parkinson Disease.